SIU Academy® - Official eLearning Portal of SIU (Société Internationale d'Urologie)

SIU-WJU Article of the Month – September 2018
Consensus recommendations for nonmuscle-invasive bladder cancer: applicable to diverse healthcare environments
Speaker(s):
MANISH TRIKAMBHAI PATEL
,
MANISH TRIKAMBHAI PATEL
Affiliations:
Badrinath Konety
Badrinath Konety
Affiliations:
SIU Academy®. Presenters F. 09/01/18; 232171 Topic: Treatment
MANISH TRIKAMBHAI PATEL
Badrinath Konety
Login now to access Regular content available to all registered users.

To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.

You may also access SIU content "anytime, anywhere" with the FREE SIU ACADEMY App for iOS and Android.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Purpose

To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the man-agement of non-muscle invasive bladder cancer (NMIBC).

Methods

A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma insitu [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments. The working group provides several recommendations on the management of NMIBC.

Results

Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and surveillance strategies.

Conclusions

NMIBC remains a common and challenging malignancy to manage. Accurate staging, grading, and risk strati-fication are critical determinants of the management and outcomes of these patients. Current tools for risk stratification are limited but informative, and should be used in clinical practice when determining diagnosis, surveillance, and treatment of NMIBC.

Keywords

Bladder cancer | Non-muscle invasive bladder cancer | Transurethral resection of bladder tumor | Staging | Diagnosis | Treatment | Surveillance | Bacillus Calmette–Guerin | Guidelines | ICUD
Purpose

To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the man-agement of non-muscle invasive bladder cancer (NMIBC).

Methods

A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma insitu [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments. The working group provides several recommendations on the management of NMIBC.

Results

Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and surveillance strategies.

Conclusions

NMIBC remains a common and challenging malignancy to manage. Accurate staging, grading, and risk strati-fication are critical determinants of the management and outcomes of these patients. Current tools for risk stratification are limited but informative, and should be used in clinical practice when determining diagnosis, surveillance, and treatment of NMIBC.

Keywords

Bladder cancer | Non-muscle invasive bladder cancer | Transurethral resection of bladder tumor | Staging | Diagnosis | Treatment | Surveillance | Bacillus Calmette–Guerin | Guidelines | ICUD
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies